NIH awards QuantaLife $6 million to build platform for detecting MRSA infections

QuantaLife, a new life science tool company developing the third generation of PCR, has received an NIH grant totaling ~$6 million over 5 years for the development of rapid, cost-effective technology for detecting methicillin-resistant Staphylococcus aureus (MRSA) infections. The grant, from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health, will fund the project.

QuantaLife is currently building a new instrument system for droplet digital™PCR, the first of its kind, that will detect and quantify DNA/RNA targets. The NIH grant will allow the company to broaden its product pipeline to build a platform for detecting the antibiotic resistant bacteria that cause MRSA infections.  Clinical testing will be done in collaboration with the University of Mississippi Medical Center.

Dr. Ben Hindson, Chief Science Officer, said, "The award provides independent validation of QuantaLife's novel ddPCR™ platform and will accelerate the development of our next-generation diagnostic platform."

SOURCE QuantaLife, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
COVID-19 vaccine successes boosted hesitancy - can trust and equity restore immunization?